RBC Capital on Mirum (MIRM): 'we could see MIRM shares up 5–10% on the EXPAND news'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Baird on Mirum Pharmaceuticals (MIRM): 'we expect upside for the stock'
October 12, 2026 9:34 AM EDTBaird analyst Brian Skorney reiterated an Outperform rating and $130.00 price target on Mirum Pharmaceuticals (NASDAQ: MIRM).
The analyst comments "Incrementally positive on EXPAND success. Mirum announced the Ph3 EXPAND basket study of maralixibat in additional cholestatic indications, about half biliary atresia patients,... More



